Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
To investigate the impact of a new class of anti-Ig autoantibodies reactive with variable heavy (VH) chain framework sequences (human anti-VH autoantibodies) on the pharmacology and safety of an anti-TNFR1 VH domain antibody (GSK1995057) in healthy human subjects.
Single-blind, randomised, placebo-controlled dose escalation study in which healthy males (n = 28) received a single GSK1995057 intravenous infusion of 0.0004, 0.002 and 0.01 mg/kg. All enrolled subjects were pre-screened for human anti-VH (HAVH) autoantibody status and prospectively stratified accordingly. Serum samples from drug-naïve, HAVH-positive volunteers were used to investigate the effect of HAVH/GSK1995057 complexes on the activation of TNFR1 and cytokine release in vitro.
Human anti-VH autoantibodies were detected in approximately 50 % of drug-naïve healthy human subjects and clinical and in vitro studies were performed to evaluate their impact on the pharmacology and safety of GSK1995057. We demonstrated that formation of HAVH autoantibody/GSK1995057 complexes activated TNFR1 and caused cytokine release in vitro in some, but not all, of the human cell types tested. When GSK1995057 was administered to healthy subjects, clinical and physiological signs of cytokine release were observed in two HAVH autoantibody-positive subjects following GSK1995057 infusion. In vitro, HAVH autoantibody levels correlated with TNFR1-dependent cytokine release and propensity for cytokine release in humans following GSK1995057 dosing.
Our data support a greater focus on the impact of pre-existing, drug-reactive autoantibodies on the development of antibody fragments and biotherapeutics targeting cell surface receptors.
- Hoffmann E, Dittrich-Breiholz O, Holtmann H, Kracht M. Multiple control of interleukin-8 gene expression. J Leukoc Biol. 2002;72:847–55.
- Weingärtner M, Siegmund D, Schlecht U, Fotin-Mleczek M, Scheurich P, Wajant H. Endogenous membrane tumor necrosis factor (TNF) is a potent amplifier of TNF receptor 1-mediated apoptosis. J Biol Chem. 2002;277:34853–9. CrossRef
- Zettlitz KA, Lorenz V, Landauer K, Münkel S, Herrmann A, Scheurich P, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs. 2010;2:639–47. CrossRef
- Bendtzen K, Hansen MB, Ross C, Svenson M. High-avidity autoantibodies to cytokines. Immunol Today. 1998;19:209–11. CrossRef
- Sauerborn M, Schellekens H. B-1 cells and naturally occurring antibodies: influencing the immunogenicity of recombinant human therapeutic proteins? Curr Opin Biotechnol. 2009;20:715–21. CrossRef
- Soos JM, Polsky RM, Keegan SP, Bugelski P, Herzyk DJ. Identification of natural antibodies to interleukin-18 in the sera of normal humans and three nonhuman primate species. Clin Immunol. 2003;109:188–96. CrossRef
- Terness P, Opelz G. Natural Anti-Immunoglobulin Autoantibodies: irrelevant by-products or immunoregulatory molecules? Int Arch Allergy Immunol. 1998;115:270–7. CrossRef
- Baumgarth N, Tung JW, Herzenberg LA. Inherent specificities in natural antibodies: a key to immune defense against pathogen invasion. Springer Semin Immunopathol. 2005;26:347–62. CrossRef
- Lutz HU, Binder CJ, Kaveri S. Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol. 2009;30:43–51. CrossRef
- Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med. 2008;358:1109–17. CrossRef
- World Medical Organization. Declaration of Helsinki. BMJ. 1996;313:1448–9.
- European Medicines Evaluation Agency (EMEA). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. Committee for medicinal products for human use, London; 2007. EMEA/CHMP/BMWP/14327/2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003946.pdf
- Food and Drug Adminstration (FDA). Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins. Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluatin and Research (CBER), Rockville, MD 20852; 2009. (draft). http://www.fda.gov/downloads/Drugs/…/Guidances/UCM192750.pdf
- Mire-Sluis AR, Barrett YC, Devanarayan V, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289:1–16. CrossRef
- Newkirk MM. Rheumatoid factors: host resistance or autoimmunity? Clin Immunol. 2002;104:1–13. CrossRef
- Terness P, Kohl I, Hübener G, et al. The natural human IgG anti-F(ab’)2 antibody recognizes a conformational IgG1 hinge epitope. J Immunol. 1995;154:6446–52.
- Poljak RJ. An idiotope-anti-idiotope complex and the structural basis of molecular mimicking. PNAS. 1994;91:1599–600. CrossRef
- Osterland CK, Harboe M, Kunkel HG. Anti-gamma-globulin factors in human sera revealed by enzymatic splitting of anti-Rh antibodies. Vox Sang. 1963;8:133–52. CrossRef
- Brezski RJ, Luongo JL, Petrone D, et al. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs. J Immunol. 2008;181:3183–92.
- Welschof M, Reineke U, Kleist C, et al. The antigen binding domain of non-idiotypic human anti-F(ab’)2 autoantibodies: study of their interaction with IgG hinge region epitopes. Hum Immunol. 1999;60:282–90. CrossRef
- Brezski RJ, Vafa O, Petrone D, et al. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. PNAS. 2009;106:17864–9. CrossRef
- Yano S, Kaku S, Suzuki K, et al. Natural antibodies against the immunoglobulin F(ab’)2 fragment cause elimination of antigens recognized by the F(ab’)2 from the circulation. Eur J Immunol. 1995;25:3128–33. CrossRef
- Avrameas S, Ternynck T. The natural autoantibodies system: between hypotheses and facts. Mol Immunol. 1993;30:1133–42. CrossRef
- Ling NR, Drysdale P. Antibodies in human sera to F(ab’)2 fragments of monoclonal and polyclonal IgG. Int Arch Allergy Appl Immunol. 1981;66:459–63. CrossRef
- Brezski RJ, Jordan RE. Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity? MAbs. 2010;2:212–20. CrossRef
- Waller M, Duma RJ, Farley Jr ED, Atkinson J. The influence of infection on titres of antiglobulin antibodies. Clin Exp Immunol. 1971;8:451–9.
- Süsal C, Daniel V, Oberg HH, et al. Striking inverse association of IgG-anti-Fab gamma antibodies and CD4 cell counts in patients with acquired immunodeficiency syndrome (AIDS)/AIDS-related complex. Blood. 1992;79:954–7.
- Süsal C, Maier H, Lorenz K, Opelz G. Association of IgA-anti-Fab autoantibodies with disease stage in head-and-neck cancer. Int J Cancer. 1994;57:47–50. CrossRef
- Fumia S, Goede JS, Fischler M, et al. Human F(ab’)2-containing immune complexes together with anti-hinge natural antibodies stimulate complement amplification in vitro and in vivo. Mol Immunol. 2008;45:2951–61. CrossRef
- Lutz HU, Fumia S. Therapeutic cleavage of IgG is dangerous in humans. Trends Immunol. 2008;29:353–4. CrossRef
- Kaku S, Yano S, Kawasaki T, et al. Comparison of the antiplatelet agent potential of the whole molecule, F(ab)2 and Fab fragments of humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Gen Pharmacol. 1996;27:435–9. CrossRef
- Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood. 2002;99:2054–9. CrossRef
- Lynn M, Rossignol DP, Wheeler JL, et al. Blocking of responses to endotoxin by e5564 in healthy volunteers with experimental endotoxemia. JID. 2003;187:631–9. CrossRef
- Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain. 1996;119:225–37. CrossRef
- Sundgren-Andersson AK, Ostlund P, Bartfai T. IL-6 is essential in TNF-alpha-induced fever. Am J Physiol. 1998;275:R2028–34.
- Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1
Journal of Clinical Immunology
Volume 33, Issue 7 , pp 1192-1203
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- domain antibody
- clinical safety
- Industry Sectors
- Author Affiliations
- 1. Research and Development, GlaxoSmithKline R&D, 709 Swedeland Road, King of Prussia, PA, 19406, USA
- 2. Research and Development, Novartis Pharma AG, Novartis Campus, 4002, Basel, Switzerland
- 3. Research and Development, GlaxoSmithKline, Gunnels Wood Road, Stevenage, SG1 2NY, UK
- 4. Clinical Pharmacology Research Unit, PAREXEL International, Watford Road, Harrow, Middlesex, HA1 3UJ, UK